Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma

NCT00870584 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

271

Enrollment

INDUSTRY

Sponsor class

Conditions

Persistent Allergic Asthma

Interventions

DRUG: Omalizumab
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals

Collaborators

[object Object]